Research programme: G-protein coupled receptor-targeting antibodies - Pfizer/Ab Initio Biotherapeutics

Drug Profile

Research programme: G-protein coupled receptor-targeting antibodies - Pfizer/Ab Initio Biotherapeutics

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Ab Initio Biotherapeutics
  • Developer Ab Initio Biotherapeutics; Pfizer
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cardiovascular disorders; Endocrine disorders; Gastrointestinal disorders; Neurological disorders

Most Recent Events

  • 14 Dec 2016 Ab Initio Biotherapeutics enters into a license agreement with Pfizer to discover therapeutic antibodies against an undisclosed target in the G-protein coupled receptor superfamily
  • 14 Dec 2016 Early research in Cardiovascular disorders in USA (unspecified route)
  • 14 Dec 2016 Early research in Endocrine disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top